Credit: Shutterstock photoProgenics PharmaceuticalsPGNX was a big mover last session, as the company saw its shares rise above 8% on the day. The move came on solid volume with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $8.32 to $10.62 in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Progenics Pharmaceuticals currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
Progenics Pharmaceuticals Inc. Price
Progenics Pharmaceuticals Inc. Price | Progenics Pharmaceuticals Inc. Quote
A better-ranked Generic-Medical Drugs stock is Cymabay Therapeutics, Inc. CBAY , which holds a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Is PGNX going up? Or down? Predict to see what others think: Up or Down
A Full-Blown Technological Breakthrough in the Making
Zacks' Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Progenics Pharmaceuticals Inc. (PGNX): Free Stock Analysis Report
CymaBay Therapeutics Inc. (CBAY): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
